'Buy China' In Procurement Schemes - Should You Worry?

A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.

China
'Buy China' Procurement Puts Foreign Companies At A Disadvantage, EUCCC Says • Source: Shutterstock

As the People's Republic of China celebrates the 70th birthday of its foundation and President Xi Jinping vows to strengthen communist rule, many are worrying that any increased dominance of state-owned enterprises (SOEs) will put international companies at a disadvantage, just at the time the government is expanding centralized procurement schemes to more health products.

The SOE has a long history in China and although many SOEs have now transformed into holding companies, many still enjoy a controlling market share in certain industry sectors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia